Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.
BCAL Diagnostics Limited has entered an exclusive agreement with ClearNote Health to distribute advanced blood tests for pancreatic and ovarian cancer in Australia and New Zealand. This strategic partnership enhances BCAL’s position in the cancer detection market by expanding its portfolio beyond breast cancer tests, potentially saving lives through early detection of high-mortality cancers.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is a company focused on oncology diagnostics, aiming to become a leader in blood-based cancer screening. It leverages partnerships with global pathology and diagnostic services to distribute its products.
Average Trading Volume: 151,556
Technical Sentiment Signal: Hold
Current Market Cap: A$24.15M
See more insights into BDX stock on TipRanks’ Stock Analysis page.